Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02926833 · ClinicalTrials.gov registry record · Phase 1
Study of Safety and Efficacy of KTE-C19 in Combination With Atezolizumab in Adults With Refractory Diffuse Large B-Cell Lymphoma (DLBCL)
A Phase 1 study, sponsored by Kite, A Gilead Company.
- Completed
- Registry status
- Phase 1
- Development phase
- 37
- Enrollment target
NCT02926833 is a Phase 1 study that has completed, run by Kite, A Gilead Company. The registered enrollment target is 37 participants.
The verdict
NCT02926833, a Phase 1 study, has completed, sponsored by Kite, A Gilead Company.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 37 participants
- Enrollment target
Study Summary
The primary objective of phase 1 is to evaluate the safety of KTE-C19 and atezolizumab combination regimens. The primary objective of phase 2 is to evaluate the efficacy of KTE-C19 and atezolizumab, as measured by complete response rate in participants with refractory diffuse large B-cell lymphoma (DLBCL). Participants who received an infusion of KTE-C19 will complete the remainder of the 15 year follow-up assessments in a separate long-term follow-up study, KT-US-982-5968 (NCT05041309).
Interventions
- DRUG Cyclophosphamide
- DRUG Fludarabine
- BIOLOGICAL Atezolizumab
- BIOLOGICAL KTE-C19
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 37 participants |
| Start Date | 2016-09-29 |
| Est. Completion | 2023-01-12 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02926833
The ClinicalTrials.gov registry entry for NCT02926833 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 37 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Kite, A Gilead Company, which has 28 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Cyclophosphamide is the first listed.
NCT02926833 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02926833 about?
NCT02926833 is a clinical study titled "Study of Safety and Efficacy of KTE-C19 in Combination With Atezolizumab in Adults With Refractory Diffuse Large B-Cell Lymphoma (DLBCL)". The primary objective of phase 1 is to evaluate the safety of KTE-C19 and atezolizumab combination regimens. The primary objective of phase 2 is to evaluate the efficacy of KTE-C19 and atezolizumab, as measured by complete response rate in participants with refractory diffuse large B-cell lymphoma ...
What is the current status of trial NCT02926833?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 37 participants. The study started on 2016-09-29. Estimated completion is 2023-01-12.
What interventions are being tested in trial NCT02926833?
The interventions under investigation include: Cyclophosphamide (DRUG), Fludarabine (DRUG), Atezolizumab (BIOLOGICAL), KTE-C19 (BIOLOGICAL).
Who is sponsoring clinical trial NCT02926833?
This trial is sponsored by Kite, A Gilead Company, which has 28 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.